{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:38:54Z","timestamp":1761824334580,"version":"3.37.3"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus L\u00fcbeck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The composition of the tumor microenvironment (TME) is conditioned by immunity and the inflammatory response. Nutritional and inflammation-based risk scores have emerged as relevant predictors of survival outcome across a variety of hematological malignancies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this retrospective multicenter trial, we ascertained the prognostic impact of established nutritional and inflammation-based risk scores [Glasgow Prognostic Score (GPS), C-reactive\u2013protein\/albumin ratio (CAR), neutrophil\u2013lymphocyte ratio (NLR), prognostic nutritional index (PNI), and prognostic index (PI)] in 209 eligible patients with histologically confirmed CD20<jats:sup>+<\/jats:sup> follicular lymphoma (FL) of WHO grade 1 (37.3%), 1\u20132 (16.3%), 2 (26.8%) or 3A (19.8%) admitted to the participating centers between January 2000 and December 2019. Characteristics significantly associated with overall or progression-free survival (OS, PFS) upon univariate analysis were subsequently included in a Cox proportional hazard model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the study cohort, the median age was 63 (range 22\u201390\u00a0years). The median follow-up period covered 99\u00a0months. The GPS and the CAR were identified to predict survival in FL patients. The GPS was the only independent predictor of OS (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001; HR 2.773; 95% CI 1.630\u20134.719) and PFS (<jats:italic>p<\/jats:italic>\u2009=\u20090.001; HR 1.995; 95% CI 1.352\u20132.944) upon multivariate analysis. Additionally, there was frequent occurrence of progression of disease within 24\u00a0months (POD24) in FL patients with a calculated GPS of 2.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The current results indicate that the GPS predicts especially OS in FL patients. Moreover, GPS was found to display disease-specific effects in regard to FL progression. These findings and potential combinations with additional established prognosticators should be further validated within prospective clinical trials.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-021-03758-5","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T12:02:43Z","timestamp":1629460963000},"page":"1789-1801","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prognostic impact of nutritional and inflammation-based risk scores in follicular lymphoma in the era of anti-CD20 targeted treatment strategies"],"prefix":"10.1007","volume":"148","author":[{"given":"Niklas","family":"Gebauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britta","family":"Mengler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svenja","family":"Kopelke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Frydrychowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"F\u00fcrschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Hackenbroch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armin","family":"Riecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus","family":"von Bubnoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Fetscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-7125","authenticated-orcid":false,"given":"Hanno M.","family":"Witte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"key":"3758_CR1","doi-asserted-by":"crossref","unstructured":"(1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 89:3909\u20133918","DOI":"10.1182\/blood.V89.11.3909"},{"key":"3758_CR2","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","volume":"19","author":"H Akaike","year":"1974","unstructured":"Akaike H (1974) A new look at the statistical model identification. IEEE Trans Autom Control AC 19:716\u2013723","journal-title":"IEEE Trans Autom Control AC"},{"key":"3758_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/sj.bjc.6602922","volume":"94","author":"AM Al Murri","year":"2006","unstructured":"Al Murri AM, Bartlett JM, Canney PA et al (2006) Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 94:227\u2013230","journal-title":"Br J Cancer"},{"key":"3758_CR4","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1182\/bloodadvances.2019032136","volume":"3","author":"S Alig","year":"2019","unstructured":"Alig S, Jurinovic V, Pastore A et al (2019) Impact of age on clinical risk scores in follicular lymphoma. Blood Adv 3:1033\u20131038","journal-title":"Blood Adv"},{"key":"3758_CR5","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1023\/A:1008265532487","volume":"9","author":"JR Anderson","year":"1998","unstructured":"Anderson JR, Armitage JO, Weisenburger DD (1998) Epidemiology of the non-Hodgkin\u2019s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin\u2019s Lymphoma Classification Project. Ann Oncol 9:717\u2013720","journal-title":"Ann Oncol"},{"key":"3758_CR6","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s12032-012-0432-4","volume":"30","author":"B Azab","year":"2013","unstructured":"Azab B, Shah N, Radbel J et al (2013) Pretreatment neutrophil\/lymphocyte ratio is superior to platelet\/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol 30:432","journal-title":"Med Oncol"},{"key":"3758_CR7","first-page":"0173","volume":"12","author":"Y Azuma","year":"2019","unstructured":"Azuma Y, Nakaya A, Fujita S et al (2019) Neutrophil-to-lymphocyte ratio (NLR) fails to predict outcome of diffuse large B cell lymphoma. Leuk Res Rep 12:0173","journal-title":"Leuk Res Rep"},{"key":"3758_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","volume":"10","author":"CL Batlevi","year":"2020","unstructured":"Batlevi CL, Sha F, Alperovich A et al (2020) Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J 10:74","journal-title":"Blood Cancer J"},{"key":"3758_CR9","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1080\/10428190701474365","volume":"48","author":"L Brepoels","year":"2007","unstructured":"Brepoels L, Stroobants S, De Wever W et al (2007) Aggressive and indolent non-Hodgkin\u2019s lymphoma: response assessment by integrated international workshop criteria. Leuk Lymphoma 48:1522\u20131530","journal-title":"Leuk Lymphoma"},{"key":"3758_CR10","doi-asserted-by":"publisher","first-page":"e51862","DOI":"10.1371\/journal.pone.0051862","volume":"7","author":"J Budczies","year":"2012","unstructured":"Budczies J, Klauschen F, Sinn BV et al (2012) Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS ONE 7:e51862","journal-title":"PLoS ONE"},{"key":"3758_CR11","first-page":"2016","volume":"269\u2013276","author":"C Casulo","year":"2016","unstructured":"Casulo C (2016) Prognostic factors in follicular lymphoma: new tools to personalize risk. Hematol Am Soc Hematol Educ Program 269\u2013276:2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"3758_CR12","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL et al (2015) Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol 33:2516\u20132522","journal-title":"J Clin Oncol"},{"key":"3758_CR13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u2013383","journal-title":"J Chronic Dis"},{"key":"3758_CR14","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1093\/annonc\/mdv376","volume":"26","author":"A Conconi","year":"2015","unstructured":"Conconi A, Lobetti-Bodoni C, Montoto S et al (2015) Life expectancy of young adults with follicular lymphoma. Ann Oncol 26:2317\u20132322","journal-title":"Ann Oncol"},{"key":"3758_CR15","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1002\/cncr.30872","volume":"123","author":"RD Dolan","year":"2017","unstructured":"Dolan RD, McMillan DC (2017) Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. Cancer 123:3855","journal-title":"Cancer"},{"key":"3758_CR16","doi-asserted-by":"publisher","first-page":"16717","DOI":"10.1038\/s41598-017-16955-5","volume":"7","author":"RD Dolan","year":"2017","unstructured":"Dolan RD, Lim J, McSorley ST et al (2017) The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: systematic review and meta-analysis. Sci Rep 7:16717","journal-title":"Sci Rep"},{"key":"3758_CR17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.critrevonc.2018.09.016","volume":"132","author":"RD Dolan","year":"2018","unstructured":"Dolan RD, Laird BJA, Horgan PG et al (2018a) The prognostic value of the systemic inflammatory response in randomised clinical trials in cancer: a systematic review. Crit Rev Oncol Hematol 132:130\u2013137","journal-title":"Crit Rev Oncol Hematol"},{"key":"3758_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41416-018-0095-9","volume":"119","author":"RD Dolan","year":"2018","unstructured":"Dolan RD, McSorley ST, Park JH et al (2018b) The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores. Br J Cancer 119:40\u201351","journal-title":"Br J Cancer"},{"key":"3758_CR19","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/ajh.24937","volume":"93","author":"A Freedman","year":"2018","unstructured":"Freedman A (2018) Follicular lymphoma: 2018 update on diagnosis and management. Am J Hematol 93:296\u2013305","journal-title":"Am J Hematol"},{"key":"3758_CR20","doi-asserted-by":"publisher","first-page":"76740","DOI":"10.18632\/oncotarget.20832","volume":"8","author":"X Hao","year":"2017","unstructured":"Hao X, Wei Y, Wei X et al (2017) Glasgow prognostic score is superior to other inflammation-based scores in predicting survival of diffuse large B-cell lymphoma. Oncotarget 8:76740\u201376748","journal-title":"Oncotarget"},{"key":"3758_CR21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s12032-012-0439-x","volume":"30","author":"W He","year":"2013","unstructured":"He W, Yin C, Guo G et al (2013) Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer. Med Oncol 30:439","journal-title":"Med Oncol"},{"key":"3758_CR22","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1159\/000495500","volume":"51","author":"L He","year":"2018","unstructured":"He L, Li H, Cai J et al (2018) Prognostic value of the glasgow prognostic score or modified Glasgow prognostic score for patients with colorectal cancer receiving various treatments: a systematic review and meta-analysis. Cell Physiol Biochem 51:1237\u20131249","journal-title":"Cell Physiol Biochem"},{"key":"3758_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10985-015-9330-3","volume":"22","author":"G Heller","year":"2016","unstructured":"Heller G, Mo Q (2016) Estimating the concordance probability in a survival analysis with a discrete number of risk groups. Lifetime Data Anal 22:263\u2013279","journal-title":"Lifetime Data Anal"},{"key":"3758_CR24","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/leu.2014.91","volume":"28","author":"W Hiddemann","year":"2014","unstructured":"Hiddemann W, Cheson BD (2014) How we manage follicular lymphoma. Leukemia 28:1388\u20131395","journal-title":"Leukemia"},{"key":"3758_CR25","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3324\/haematol.2011.042531","volume":"96","author":"H Horn","year":"2011","unstructured":"Horn H, Schmelter C, Leich E et al (2011) Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. Haematologica 96:1327\u20131334","journal-title":"Haematologica"},{"key":"3758_CR26","doi-asserted-by":"crossref","unstructured":"Jurinovic VPV, Oestergaard MZ, Knapp A, Mundt K, Araf S, Richter J, Fitzgibbon J, Klapper W, Marcus RE, Davies A, Herold M, Hiddemann W, Unterhalt M, Hoster E, Weigert O (2019) Evaluation of the m7-FLIPI in patients with follicular lymphoma treated within the Gallium Trial: EZH2 mutation status may be a predictive marker for differential efficacy of chemotherapy. Presented at the Blood, Atlanta, Florida, United States","DOI":"10.1182\/blood-2019-130208"},{"key":"3758_CR27","first-page":"1187","volume":"31","author":"H Kaba","year":"2004","unstructured":"Kaba H, Fukuda H, Yamamoto S et al (2004) Reliability at the National Cancer Institute-Common Toxicity Criteria version 2.0. Gan to Kagaku Ryoho 31:1187\u20131192","journal-title":"Gan to Kagaku Ryoho"},{"key":"3758_CR28","first-page":"52","volume":"17","author":"G Kasymjanova","year":"2010","unstructured":"Kasymjanova G, MacDonald N, Agulnik JS et al (2010) The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. Curr Oncol 17:52\u201358","journal-title":"Curr Oncol"},{"key":"3758_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0002-9440(10)63313-5","volume":"165","author":"T Katzenberger","year":"2004","unstructured":"Katzenberger T, Ott G, Klein T et al (2004) Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component. Am J Pathol 165:481\u2013490","journal-title":"Am J Pathol"},{"key":"3758_CR30","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1158\/1078-0432.CCR-16-1576","volume":"23","author":"C Keane","year":"2017","unstructured":"Keane C, Gould C, Jones K et al (2017) The T-cell receptor repertoire influences the tumor microenvironment and is associated with survival in Aggressive B-cell lymphoma. Clin Cancer Res 23:1820\u20131828","journal-title":"Clin Cancer Res"},{"key":"3758_CR31","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/ng.3413","volume":"47","author":"H Kretzmer","year":"2015","unstructured":"Kretzmer H, Bernhart SH, Wang W et al (2015) DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control. Nat Genet 47:1316\u20131325","journal-title":"Nat Genet"},{"key":"3758_CR32","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/ajh.23422","volume":"88","author":"YJ Li","year":"2013","unstructured":"Li YJ, Jiang WQ, Huang JJ et al (2013) The Glasgow Prognostic Score (GPS) as a novel and significant predictor of extranodal natural killer\/T-cell lymphoma, nasal type. Am J Hematol 88:394\u2013399","journal-title":"Am J Hematol"},{"key":"3758_CR33","doi-asserted-by":"publisher","first-page":"e395","DOI":"10.5301\/jbm.5000222","volume":"31","author":"ZL Liu","year":"2016","unstructured":"Liu ZL, Zeng TT, Zhou XJ et al (2016) Neutrophil-lymphocyte ratio as a prognostic marker for chemotherapy in advanced lung cancer. Int J Biol Markers 31:e395\u2013e401","journal-title":"Int J Biol Markers"},{"key":"3758_CR34","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/hon.2359","volume":"35","author":"R Marcheselli","year":"2017","unstructured":"Marcheselli R, Bari A, Tadmor T et al (2017) Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients. Hematol Oncol 35:561\u2013566","journal-title":"Hematol Oncol"},{"key":"3758_CR35","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1093\/annonc\/mdh406","volume":"15","author":"S Montoto","year":"2004","unstructured":"Montoto S, Lopez-Guillermo A, Altes A et al (2004) Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol 15:1484\u20131489","journal-title":"Ann Oncol"},{"key":"3758_CR36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s12032-014-0287-y","volume":"31","author":"T Moriwaki","year":"2014","unstructured":"Moriwaki T, Ishige K, Araki M et al (2014) Glasgow Prognostic Score predicts poor prognosis among advanced biliary tract cancer patients with good performance status. Med Oncol 31:287","journal-title":"Med Oncol"},{"key":"3758_CR37","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.1182\/bloodadvances.2020002944","volume":"4","author":"D Nann","year":"2020","unstructured":"Nann D, Ramis-Zaldivar JE, Muller I et al (2020) Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease. Blood Adv 4:5652\u20135665","journal-title":"Blood Adv"},{"key":"3758_CR38","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood.V68.4.837.837","volume":"68","author":"BN Nathwani","year":"1986","unstructured":"Nathwani BN, Metter GE, Miller TP et al (1986) What should be the morphologic criteria for the subdivision of follicular lymphomas? Blood 68:837\u2013845","journal-title":"Blood"},{"key":"3758_CR39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3960\/jslrt.52.77","volume":"52","author":"A Numata","year":"2012","unstructured":"Numata A, Tomita N, Fujimaki K et al (2012) Retrospective study of the utility of FLIPI\/FLIPI-2 for follicular lymphoma patients treated with R-CHOP. J Clin Exp Hematop 52:77\u201379","journal-title":"J Clin Exp Hematop"},{"key":"3758_CR40","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","volume":"16","author":"A Pastore","year":"2015","unstructured":"Pastore A, Jurinovic V, Kridel R et al (2015) Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 16:1111\u20131122","journal-title":"Lancet Oncol"},{"key":"3758_CR41","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/sj.bjc.6606087","volume":"104","author":"MJ Proctor","year":"2011","unstructured":"Proctor MJ, Morrison DS, Talwar D et al (2011) An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 104:726\u2013734","journal-title":"Br J Cancer"},{"key":"3758_CR42","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1182\/blood-2018-07-865428","volume":"133","author":"X Qu","year":"2019","unstructured":"Qu X, Li H, Braziel RM et al (2019) Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016. Blood 133:81\u201393","journal-title":"Blood"},{"key":"3758_CR43","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/bjh.15054","volume":"180","author":"JP Reddy","year":"2018","unstructured":"Reddy JP, Hernandez M, Gunther JR et al (2018) Pre-treatment neutrophil\/lymphocyte ratio and platelet\/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma. Br J Haematol 180:545\u2013549","journal-title":"Br J Haematol"},{"key":"3758_CR44","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/bjh.17083","volume":"193","author":"J Rieken","year":"2020","unstructured":"Rieken J, Bernard V, Witte HM et al (2020) Exhaustion of tumour-infiltrating T-cell receptor repertoire diversity is an age-dependent indicator of immunological fitness independently predictive of clinical outcome in Burkitt lymphoma. Br J Haematol 193:138\u2013149","journal-title":"Br J Haematol"},{"key":"3758_CR45","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","volume":"116","author":"M Sant","year":"2010","unstructured":"Sant M, Allemani C, Tereanu C et al (2010) Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 116:3724\u20133734","journal-title":"Blood"},{"key":"3758_CR46","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s00268-014-2844-0","volume":"39","author":"H Shiba","year":"2015","unstructured":"Shiba H, Misawa T, Fujiwara Y et al (2015) Glasgow prognostic score predicts outcome after surgical resection of gallbladder cancer. World J Surg 39:753\u2013758","journal-title":"World J Surg"},{"key":"3758_CR47","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s10120-010-0554-3","volume":"13","author":"H Shimada","year":"2010","unstructured":"Shimada H, Takiguchi N, Kainuma O et al (2010) High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer 13:170\u2013176","journal-title":"Gastric Cancer"},{"key":"3758_CR48","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P et al (2004) Follicular lymphoma international prognostic index. Blood 104:1258\u20131265","journal-title":"Blood"},{"key":"3758_CR49","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3324\/haematol.2017.165415","volume":"102","author":"WBC Stevens","year":"2017","unstructured":"Stevens WBC, Mendeville M, Redd R et al (2017) Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. Haematologica 102:1413\u20131423","journal-title":"Haematologica"},{"key":"3758_CR50","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375\u20132390","journal-title":"Blood"},{"key":"3758_CR51","doi-asserted-by":"publisher","first-page":"6685","DOI":"10.21873\/anticanres.14692","volume":"40","author":"A Szumera-CieCkiewicz","year":"2020","unstructured":"Szumera-CieCkiewicz A, Poleszczuk J, Paszkiewicz-Kozik E et al (2020) EZH2 expression in follicular lymphoma is variable and independent from the progression of disease within 24 months of first treatment. Anticancer Res 40:6685\u20136697","journal-title":"Anticancer Res"},{"key":"3758_CR52","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.mayocp.2015.03.025","volume":"90","author":"T Tadmor","year":"2015","unstructured":"Tadmor T, Bari A, Marcheselli L et al (2015) Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis hodgkin lymphoma: evaluation based on data from 1450 patients. Mayo Clin Proc 90:756\u2013764","journal-title":"Mayo Clin Proc"},{"key":"3758_CR53","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1093\/annonc\/mdp053","volume":"20","author":"SA van de Schans","year":"2009","unstructured":"van de Schans SA, Steyerberg EW, Nijziel MR et al (2009) Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting. Ann Oncol 20:1697\u20131702","journal-title":"Ann Oncol"},{"key":"3758_CR54","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/0959-8049(92)90510-9","volume":"28A","author":"E Verger","year":"1992","unstructured":"Verger E, Salamero M, Conill C (1992) Can Karnofsky performance status be transformed to the Eastern Cooperative Oncology Group scoring scale and vice versa? Eur J Cancer 28A:1328\u20131330","journal-title":"Eur J Cancer"},{"key":"3758_CR55","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/bjh.15198","volume":"184","author":"H Witte","year":"2019","unstructured":"Witte H, Biersack H, Kopelke S et al (2019) The Glasgow prognostic score at diagnosis is an independent predictor of survival in advanced stage classical Hodgkin lymphoma. Br J Haematol 184:869\u2013873","journal-title":"Br J Haematol"},{"key":"3758_CR56","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3390\/cancers12040921","volume":"12","author":"HM Witte","year":"2020","unstructured":"Witte HM, Bonorden B, Riecke A et al (2020) The Glasgow prognostic score at diagnosis is a predictor of clinical outcome in patients with multiple myeloma undergoing autologous haematopoietic stem cell transplantation. Cancers (basel) 12:921","journal-title":"Cancers (basel)"},{"key":"3758_CR57","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.jtho.2016.04.029","volume":"11","author":"M Yotsukura","year":"2016","unstructured":"Yotsukura M, Ohtsuka T, Kaseda K et al (2016) Value of the Glasgow Prognostic Score as a prognostic factor in resectable non-small cell lung cancer. J Thorac Oncol 11:1311\u20131318","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03758-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03758-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03758-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T04:29:14Z","timestamp":1655094554000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03758-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["3758"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03758-5","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2021,8,20]]},"assertion":[{"value":"25 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest. This retrospective study was approved by the ethics committee of the University of Luebeck (Reference-no 18-037) and conducted in accordance with the Declaration of Helsinki. Written informed consent referred to routine diagnostics and academic assessment of the archived biopsy specimen as well as transfer of clinical data was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}